Tag Archives: technology

Hot Investor Mandate: Multi-Billion AUM VC Firm Invests Up to $20M in Innovative Biotech and Medtech Platforms and Products

27 Jan

A venture capital platform specialized in life sciences and medical technology manages multiple funds with total assets under management of approximately $1.5B. The firm has been operating since 2014 and is managed by a professional team with diverse and deep industry experience. To date, the firm has completed more than 90 investments in high-growth-potential companies. Typical allocation sizes for their RMB funds range from RMB 30M to RMB 150M, with the ability to invest up to RMB 200M. For the USD fund, typical investments range from $5-10M, with the ability to invest up to $20M. 

The firm is open to investing globally across the broader biomedical sector, including medtech and biotech or therapeutics. The firm focuses on technology-driven, innovative platforms and products that demonstrate clear differentiation and meaningful value creation for patients and the healthcare system overall. Within biotech and therapeutics, the firm prefers companies at the angel or venture stages, particularly those addressing significant unmet clinical needs. 

From a company perspective, the firm prefers opportunities that are technology-driven, commercially viable, and capable of solving real-world healthcare problems. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Corporate VC Arm of Global Pharma Strategically Invests in Pre-Clinical Therapeutics in Areas Including Oncology, CNS, Immunology

27 Jan

A corporate venture capital arm of a global pharmaceutical company with a long operating history and an international footprint is actively seeking new investments. The parent organization operates worldwide and has expanded its global reach through strategic acquisitions in recent years. As part of its broader open innovation strategy, the parent organization actively pursues in- and out-licensing, early-stage partnerships, and strategic investments. The firm is responsible for executing strategic investments that support future partnering opportunities and help build the parent organization’s therapeutic pipeline. 

The firm was established a few years ago and operates from the United States. The firm manages an evergreen fund and focuses on pre-clinical startups with differentiated platforms and first-in-class programs in human therapeutics. The firm participates in Seed and Series A financing rounds, typically investing up to USD $5M initially, with the ability to invest up to USD $10M per company through follow-on capital. The firm is open to engaging with companies globally and has built a portfolio of more than a dozen investments, primarily across Europe and the United States. 

The firm targets pre-clinical to pre-IND, in-human therapeutics companies. Key areas of interest include oncology, neurology, immunology, and specialty disease areas such as fibrosis, endocrine disorders, and rare genetic diseases. The firm is modality-agnostic and considers small molecules, antibodies, nucleic acid-based therapies, and gene therapies. The firm does not invest in medical devices or diagnostics. 

The firm does not lead financing rounds. When co-investing or participating in syndicated rounds, the firm requires a board observer seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , ,

Hot Investor Mandate: VC Firm With Multiple Life Science-Focused Funds Seeks Early-Stage Therapeutics and AI-Enabled Technologies 

27 Jan

A venture capital platform associated with a leading global life sciences services provider manages multiple funds and focuses on investing in early-stage life science companies. The firm’s investment sweet spot spans from Seed through Series B stages. Initial check sizes typically range from USD $2–10M, with the ability to provide follow-on capital. The firm is open to both leading and co-investing and considers board or observer seats on a case-by-case basis. Backed by a major contract research organization, the firm leverages deep expertise in biotech research and development to deliver value beyond capital. 

The firm invests in biotech therapeutics, including small molecules, biologics, and drug discovery programs. Key areas of interest include oncology, immunology and inflammation, central nervous system diseases, and metabolic diseases, covering a broad range of commonly pursued indications. The firm evaluates opportunities from the pre-IND stage through Phase I clinical trials. In addition, the firm focuses on innovative AI-enabled healthcare opportunities with strong technological differentiation, including AI-integrated medical devices such as surgical robotics, brain–computer interfaces, and smart imaging systems, as well as AI-driven diagnostics, drug discovery acceleration platforms, and intelligent healthcare solutions designed to improve clinical efficiency and data-driven decision-making. 

The firm does not impose specific requirements regarding the composition of a company’s management team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Early-Stage Focused Venture Fund Looks for Neuropsychiatric Opportunities from Pre-Seed to Series A Rounds

27 Jan

A venture capital firm focused on early-stage neuropsychiatric opportunities invests from Pre-Seed to Series A stages, with initial check sizes typically ranging from USD $50K to $1M. The firm is open to acting as the first institutional investor and may provide follow-on capital. The firm is open to both leading and co-investing and will consider board or observer seats on a case-by-case basis. The firm participates in both traditional equity rounds and SAFE agreements. While the firm primarily focuses on U.S.-based companies, the firm is also open to global opportunities. 

The firm invests in neuropsychiatric treatments and technologies aimed at improving mental health and general wellness. Areas of interest include psychedelic medicine, brain–computer interfaces, therapeutic platforms, precision diagnostics, and related technologies. For biotech opportunities, the firm prefers assets that are at or near the IND stage. For medtech opportunities, the firm is willing to engage earlier in the development process. 

The firm does not have strict requirements regarding management team composition but strongly prefers to work with founders who have prior pharmaceutical or biotech industry experience or a demonstrated track record of successful entrepreneurship. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Winners Announced at RESI JPM 2026 Innovator’s Pitch Challenge 

21 Jan

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

RESI JPM 2026 brought together more than 90 innovative life science and healthcare companies over two days, creating one of the most competitive and high-impact RESI conferences to date. A centerpiece of the meeting was the Innovator’s Pitch Challenge (IPC), which provided early-stage companies with a powerful platform to present their technologies, engage directly with investors, and gain visibility within the global life sciences ecosystem.

IPC finalists delivered six-minute pitch presentations, followed by a seven-minute interactive Q&A with a panel of experienced investor judges. Beyond the stage, each participating company showcased its technology at a dedicated table in the RESI Exhibition Hall, enabling deeper conversations during partnering meetings and informal discussions throughout the conference.

A defining element of the Innovator’s Pitch Challenge is its attendee-driven voting model. Registered RESI JPM attendees—including startup executives, venture investors, and industry experts—were given RESI cash at check-in and used it to “invest” in the IPC companies they believed demonstrated the strongest potential. Voting decisions reflected not only pitch performance, but also the companies’ responses during Q&A, one-on-one interactions at their exhibition tables, and follow-up meetings held during the conference.

Life Science Nation is proud to announce the top three winners of the RESI JPM 2026 Innovator’s Pitch Challenge:

1st Place 2nd Place 3rd Place
Oncovita VerImmune Proseek-Bio
Oncovita VerImmune Proseek Bio

Participating companies were organized into 24 sector-focused pitch sessions, each featuring four companies and evaluated by expert judging panels. In addition to the top three overall winners, judges recognized standout companies for exceptional science, compelling business models, and strong execution.

Judges’ Picks:

Looking ahead: Applications are now open for Life Science Nation’s next European conference, taking place in Portugal on March 23, 2026. Companies interested in pitching can apply here. 

Apply to Pitch at RESI Europe 2026

Tags: , , , , , , , , , , , ,

RESI 2026: Sponsorship That Delivers Visibility, Connection, and Real Engagement 

21 Jan

By Max Braht, Director of Business Development, LSN

Max-Braht-Headshot

The RESI (Redefining Every Stage of Investment) Conference Series, produced by Life Science Nation (LSN), has become a cornerstone event series for the early-stage life science ecosystem. Designed to bring together innovators, investors, and strategic partners, RESI offers a highly curated environment where capital formation, partnership development, and brand visibility intersect.

In 2026, the RESI Series continues its global reach through a combination of in-person conferences and structured virtual partnering, offering sponsors year-round exposure and repeated touchpoints with a highly targeted audience.

A Global Series Built for Impact

The 2026 RESI Series includes multiple events across major life science hubs:

  • RESI Europe 2026 – Lisbon, March 23 (with virtual partnering March 24–25)
  • RESI June at San Diego 2026 – June 22 (with virtual partnering June 23–24, 29)
  • RESI Boston 2026 – September 22–23 (with follow-up virtual partnering September 25, 28)

Across these events, RESI convenes companies spanning therapeutics, diagnostics, medical devices, digital health, and enabling technologies, alongside venture capital firms, family offices, strategic investors, and corporate partners. Sponsors benefit from consistent brand presence across the series while engaging with a community focused on early-stage innovation and investment readiness.

Why Organizations Sponsor RESI

RESI sponsorship is structured to go beyond logo placement. Sponsors are integrated into the fabric of the conference experience, with benefits that can include:

  • High-visibility branding across pre-event marketing, onsite signage, and digital platforms
  • Exhibit opportunities in high-traffic networking areas during in-person events
  • Thought-leadership placement, including workshops, moderated sessions, and published articles distributed to LSN’s global audience
  • Targeted networking and partnering, supported by RESI’s proprietary matchmaking platform
  • Post-event attendee access, enabling meaningful follow-up with investors, founders, and decision-makers

Tiered sponsorship options allow organizations to align their level of involvement with specific business development, visibility, or ecosystem-building goals, while optional add-ons provide further customization.

Who Benefits from Sponsoring RESI

RESI sponsorship is designed to support a wide range of organizations across the life science ecosystem. Sponsors consistently report value not only in exposure, but in the relevance and quality of connections made.

Service Providers
CROs, CDMOs, legal, IP, regulatory, manufacturing, data, and commercialization services (e.g., McDermot Will & Emery, Biometas)

  • Direct access to early-stage companies actively building pipelines and seeking partners
  • Visibility among founders, executives, and investors at key decision-making stages
  • Opportunities to demonstrate expertise through workshops, articles, and curated sessions

Organizations such as Medmarc exemplify the value of sustained participation. Their consistent presence across multiple RESI conferences has helped establish familiarity and trust with early-stage companies, positioning them as a known and credible partner as those companies progress from formation through later stages of growth.

Regional Organizations and Innovation Hubs
Economic development groups, accelerators, incubators, trade organizations, and government-backed initiatives (past sponsors include Brisbane Economic Development Agency (BEDA), Kobe Biomedical Innovation Cluster, (KBIC) and Israel Export Institute (IEI))

  • A global platform to showcase regional ecosystems and portfolio companies
  • The ability to host demo days, pitch sessions, or dedicated tracks aligned with regional priorities
  • Increased international exposure to investors and strategic partners

Investors and Strategic and Corporate Partners
Venture capital, corporate venture, family offices, and strategic partners (past sponsors include, Muscular Dystrophy Association (MDA), Johnson & Johnson Innovation JLABS, and Eli Lilly)

  • Targeted visibility among investment- or partnering-ready startups across multiple modalities
  • Access to curated partnering and company intelligence through the RESI platform
  • Opportunities to participate in panels, pitch sessions, and thought-leadership programming
  • Structured environments for scouting, relationship-building, and ecosystem engagement
  • Brand alignment with a trusted, innovation-focused conference series

Sponsor Spotlight: How Organizations Activated Their Presence at RESI JPM 2026

While RESI JPM 2026 has already taken place, it provides a strong example of how sponsors can actively engage with the RESI platform — not just through visibility, but through programming and participation that creates tangible value.

One notable example is Kobe Biomedical Innovation Cluster (KBIC), a Gold Sponsor of RESI JPM 2026. KBIC leveraged its sponsorship to host the Kansai Life Sciences Accelerator Program (KLSAP) Demo Day, a dedicated session that highlighted emerging life science companies from its accelerator cohort.

Through this activation, KBIC provided startups with direct access to international investors and strategic partners, while reinforcing its role as a global connector within the life science innovation ecosystem. Rather than serving as a passive sponsor, KBIC used the RESI platform to advance its mission, support portfolio companies, and foster cross-border collaboration.

Similarly, Trillium BIO capitalized on both the high foot traffic generated by its exhibit booth and RESI’s partnering platform to schedule a large number of targeted meetings for its team. By combining in-person visibility with structured partnering, Trillium BIO maximized engagement efficiency and ensured meaningful conversations with potential clients and partners throughout the event.

What Successful Sponsors Do Differently

Examples from RESI JPM illustrate several effective sponsorship strategies that carry forward across the 2026 Series:

They integrate into the program.
Sponsors that host workshops, demo days, or curated sessions create natural engagement opportunities and attract aligned audiences.

They align sponsorship with strategy.
Whether the goal is pipeline development, geographic expansion, or investor visibility, effective sponsors use RESI to support broader organizational objectives.

They prioritize connection over exposure alone.
By leveraging partnering tools, curated meetings, and live engagement opportunities, sponsors maximize the quality of interactions — not just the quantity.

Looking Ahead

As the RESI 2026 Series continues across Europe and the United States, sponsors can build sustained visibility while actively shaping conversations at the forefront of life science innovation. The success of sponsor activations at past events demonstrates that RESI is not simply a conference series but a platform for meaningful engagement, partnership building, and long-term impact within the global life science community.

For more information about sponsorship opportunities across the RESI 2026 Series, contact us at sales@lifesciencenation.com. We look forward to discussing your needs and exploring how RESI can support your goals.

Tags: , , , , , , , , , , , , , , , , , , , , ,

Myonerv: RESI London Innovator’s Pitch Challenge Winner Advancing Stroke Rehabilitation

21 Jan

Interview with Sam Kamali, CEO of Myonerv

Myonerv is developing a new approach to stroke rehabilitation that aims to expand access to intensive, effective therapy beyond the clinic. Following their recent win at the Innovator’s Pitch Challenge at RESI London, the team is advancing a wearable neurotechnology designed to help patients regain upper-limb movement through intention-driven stimulation and remote clinical support. We spoke with Myonerv to learn more about the problem they are addressing, their technology, and what comes next as they move toward clinical trials and global partnerships. 

Sam Kamali
 CaitiCaitlin Dolegowski

Caitlin Dolegowski (CD): For readers who may be new to Myonerv, how do you describe the company’s mission and core technology?

Sam Kamali (SK): Myonerv is a breakthrough British neurotechnology solution designed to transform stroke rehabilitation through an active, remote-operated wearable medical device that restores movement in patients with post-stroke upper-limb paralysis (paresis). A wearable, non-invasive neurostimulator that helps retrain movement after stroke by detecting a patient’s intention to move and delivering targeted electrical stimulation to augment that movement. This “closed-loop” approach is supported by scientific evidence showing that synchronising stimulation with a person’s voluntary effort can enhance neuroplasticity – the brain’s ability to rewire and relearn lost movements.

Unlike traditional electrical stimulators, Myonerv uses flexible bioelectronic materials to create soft, reusable electrodes that conform comfortably to the arm. The system is designed to be lightweight, easy to apply, and suitable for both clinical and home environments. It will also allow therapists to monitor progress and support patients remotely, helping expand rehabilitation capacity without increasing staff burden.

CD: What problem are you addressing, and why is now the right time for your approach?

SK: Partial paralysis after a Stroke affects 70% of all survivors, approximately 900,000 new patients annually in the UK, DACH and USA. Despite clear evidence that intensive, early, and consistent rehabilitation improves outcomes, most patients in the UK receive only 45 minutes of therapy per day in hospital and as little as 1 hour per week after discharge – far below nationally recommended 3 hours per day. We believe the resulting “plateau” in stroke recovery is not biological, but due to the lack of therapy access and intensity.

Myonerv directly addresses this challenge by developing a first-in-class wearable, closed-loop neurostimulator that enables continuous, intention-driven rehabilitation both in-clinic and at home. It combines bioelectronic sensing, software-assisted control loops, reusable polymer electrodes and remote therapist connectivity (capabilities not currently available in NHS or international markets). The innovation advances beyond the state of the art in its miniaturisation, accuracy, sustainability, and ability to extend clinical rehabilitation into the community setting.

CD: What stood out most to you about competing in—and winning—the Innovator’s Pitch Challenge at RESI London?

SK: “It’s so refreshing to hear such a good pitch, after such a long time”. These were the words that stuck with us from our judge, Soyoung Park, General Partner at 1004 Ventures.

This echoed the depth of excitement from investors throughout the event. The judges and audience deeply understood both the clinical problem and the commercial challenge of scaling medical technologies within healthcare systems. People were enthusiastic about the prospect of a remote-controlled rehabilitation device that can exponentially increase the amount of therapy received by patients. Winning wasn’t just validation of the technology - it was validation of the need and our ability to change the state of healthcare worldwide.

CD: How has the exposure from RESI London impacted conversations with investors or strategic partners so far?

SK: RESI London has materially accelerated conversations. Since the event, we’ve seen increased inbound interest from international investors and strategic partners across Europe and the US, particularly those focused on neurotechnology, digital health, and rehabilitation.

The win has acted as a strong credibility signal – shortening diligence cycles and shifting discussions toward clinical milestones, regulatory strategy, and partnership structures rather than basic validation. It has also opened doors to potential manufacturing and healthcare delivery partners who see Myonerv as an international platform, not just a single product.

CD: Where is Myonerv currently in terms of fundraising or partnership strategy?

SK: We have officially opened a £2 million pre-seed priced round. Our strategy is to combine the £215k in non-dilutive funding with targeted private investment to de-risk the technology before scaling. What is promising is that we are receiving non-dilutive funding faster than we can announce it, with a recent admission into the Founders Factory x Innovate UK (Hospital to Home) Biomedical Catalyst Accelerator, which enables a£100k grant for us to perform our first in-patient trials.

This touches on our recent partnership arrangements, as we are working closely with several patient networks and the Cambridgeshire & Peterborough Foundation Trust (CPFT), an NHS Trust overseeing hospital networks across the East of England. CPFT has agreed to sponsor our clinical trials, which fast-tracks the process for trial approvals, recruitment and secure documentation of data. CPFT has shown great enthusiasm in being our first pilot sites for Myonerv. This is only a small part of our partnership arrangements, as we have several more with other hospitals across the UK who have given us Letters of Interest to give Myonerv to 1,200 patients per year once the device is available in the market.

We are now looking to build on the network we have built in Cambridge thanks to the £120k grant won from ARIA as part of Cambridge NeuroWorks, tasked with developing a first-in-class scalable neural interface for the world. Our next step is to visit RESI JPM in San Francisco on January 12th 2026 to create more partnerships with the US network as we look to expand our reach globally.

CD: What milestones are you most focused on over the next 12–18 months?

SK: Our primary focus is delivering on the tech. We are currently finalizing our functional prototype with the Manufacturing Technology Centre, a major UK-based factory, to test on participants with approvals from the University of Cambridge. Our shiny new prototype will be ready in time for an exciting Myonerv demo at RESI Europe in Lisbon, on 23rd March 2026!

We are then looking to build on this to develop a TRL6/7 alpha device and completing a feasibility clinical study in stroke survivors. In parallel, we are advancing our regulatory pathway, quality management systems, and health-economic evidence to support adoption by healthcare providers. Having secured regulatory and commercial partners who will help navigate our pathway through into international markets.

We are simultaneously focused on strengthening manufacturing readiness, expanding our clinical and patient engagement network, and closing our pre-seed round. Together, these milestones position Myonerv for scale - clinically, commercially, and globally.

Apply to Pitch at RESI Europe 2026

Tags: , , , , , , , , , , , , , , , , , , , , , , , ,

← Older Entries
Newer Entries →